ZA200209439B - Barbituric acid analogs as therapeutic agents. - Google Patents
Barbituric acid analogs as therapeutic agents. Download PDFInfo
- Publication number
- ZA200209439B ZA200209439B ZA200209439A ZA200209439A ZA200209439B ZA 200209439 B ZA200209439 B ZA 200209439B ZA 200209439 A ZA200209439 A ZA 200209439A ZA 200209439 A ZA200209439 A ZA 200209439A ZA 200209439 B ZA200209439 B ZA 200209439B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound according
- optionally substituted
- compound
- amended sheet
- ring atoms
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 5
- 150000007656 barbituric acids Chemical class 0.000 title abstract description 7
- 229940124597 therapeutic agent Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 173
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 30
- 230000033115 angiogenesis Effects 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 17
- 230000003993 interaction Effects 0.000 claims abstract description 17
- 201000011510 cancer Diseases 0.000 claims abstract description 13
- 230000002062 proliferating effect Effects 0.000 claims abstract description 13
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims abstract 4
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims abstract 4
- 125000006413 ring segment Chemical group 0.000 claims description 30
- -1 phenyl-ethenyl Chemical group 0.000 claims description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 125000004122 cyclic group Chemical group 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 125000001931 aliphatic group Chemical group 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 7
- 125000003368 amide group Chemical group 0.000 claims description 7
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 7
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical compound OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- 150000001204 N-oxides Chemical class 0.000 claims description 4
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 4
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000005561 phenanthryl group Chemical group 0.000 claims description 2
- 150000003568 thioethers Chemical class 0.000 claims 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims 1
- 235000011613 Pinus brutia Nutrition 0.000 claims 1
- 241000018646 Pinus brutia Species 0.000 claims 1
- 231100000504 carcinogenesis Toxicity 0.000 abstract description 6
- 208000005623 Carcinogenesis Diseases 0.000 abstract description 5
- 230000036952 cancer formation Effects 0.000 abstract description 5
- 238000000338 in vitro Methods 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 23
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 description 18
- 101000882390 Homo sapiens Histone acetyltransferase p300 Proteins 0.000 description 18
- 101000978776 Mus musculus Neurogenic locus notch homolog protein 1 Proteins 0.000 description 18
- 206010021143 Hypoxia Diseases 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- 102100030907 Aryl hydrocarbon receptor nuclear translocator Human genes 0.000 description 11
- 101000690445 Caenorhabditis elegans Aryl hydrocarbon receptor nuclear translocator homolog Proteins 0.000 description 11
- 101000793115 Homo sapiens Aryl hydrocarbon receptor nuclear translocator Proteins 0.000 description 11
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 230000007954 hypoxia Effects 0.000 description 7
- 230000001146 hypoxic effect Effects 0.000 description 7
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 230000027455 binding Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000005166 vasculature Anatomy 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 101710165425 Alpha-enolase Proteins 0.000 description 2
- 102100038910 Alpha-enolase Human genes 0.000 description 2
- 101710184673 Enolase 1 Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000001099 axilla Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000020874 response to hypoxia Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- AMATXUCYHHHHHB-UHFFFAOYSA-N 5,5-dibromo-1,3-diazinane-2,4,6-trione Chemical compound BrC1(Br)C(=O)NC(=O)NC1=O AMATXUCYHHHHHB-UHFFFAOYSA-N 0.000 description 1
- MENIJRPFVLNJIH-UHFFFAOYSA-N 5-benzyl-1,3-diazinane-2,4,6-trione Chemical class O=C1NC(=O)NC(=O)C1CC1=CC=CC=C1 MENIJRPFVLNJIH-UHFFFAOYSA-N 0.000 description 1
- CMWDWOZYVQQAMI-UHFFFAOYSA-N 5-benzylidene-1,3-diazinane-2,4,6-trione Chemical class O=C1NC(=O)NC(=O)C1=CC1=CC=CC=C1 CMWDWOZYVQQAMI-UHFFFAOYSA-N 0.000 description 1
- CRVVMZCBPNDWJE-UHFFFAOYSA-N 5-bromo-5-phenyl-1,3-diazinane-2,4,6-trione Chemical compound C=1C=CC=CC=1C1(Br)C(=O)NC(=O)NC1=O CRVVMZCBPNDWJE-UHFFFAOYSA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 241001135700 Arcanobacterium haemolyticum Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 241000186245 Corynebacterium xerosis Species 0.000 description 1
- 101710173353 Cytotoxicity-associated immunodominant antigen Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 101100113485 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) chs-3 gene Proteins 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
- 102000002131 PAS domains Human genes 0.000 description 1
- 108050009469 PAS domains Proteins 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108091006296 SLC2A1 Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000006405 Uridine phosphorylase Human genes 0.000 description 1
- 108010019092 Uridine phosphorylase Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000006538 anaerobic glycolysis Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000007959 normoxia Effects 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001639 phenylmethylene group Chemical group [H]C(=*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000026341 positive regulation of angiogenesis Effects 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0013655.6A GB0013655D0 (en) | 2000-06-05 | 2000-06-05 | Therapeutic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200209439B true ZA200209439B (en) | 2003-11-20 |
Family
ID=9893008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200209439A ZA200209439B (en) | 2000-06-05 | 2002-11-20 | Barbituric acid analogs as therapeutic agents. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20030229108A1 (fr) |
| EP (1) | EP1305026B1 (fr) |
| JP (1) | JP2003535123A (fr) |
| CN (1) | CN1433312A (fr) |
| AT (1) | ATE431149T1 (fr) |
| AU (1) | AU2001260504A1 (fr) |
| BR (1) | BR0111438A (fr) |
| CA (1) | CA2410311C (fr) |
| DE (1) | DE60138709D1 (fr) |
| GB (1) | GB0013655D0 (fr) |
| IL (1) | IL153014A0 (fr) |
| NZ (1) | NZ522779A (fr) |
| WO (1) | WO2001093841A2 (fr) |
| ZA (1) | ZA200209439B (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2384428A (en) * | 2002-01-29 | 2003-07-30 | Thromb X Nv | Inhibitors of HIF |
| US7288546B1 (en) * | 2003-02-20 | 2007-10-30 | University Of Central Florida | Method and compound for inhibition of cell death |
| WO2003074497A1 (fr) * | 2002-03-01 | 2003-09-12 | Pintex Pharmaceutical, Inc. | Composes de modulation de pin1 et methodes d'utilisation associees |
| GB0206711D0 (en) | 2002-03-21 | 2002-05-01 | Isis Innovation | HIF Inhibitor |
| GB2387172A (en) * | 2002-03-28 | 2003-10-08 | Pantherix Ltd | [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials |
| GB2386892A (en) * | 2002-03-28 | 2003-10-01 | Pantherix Ltd | Carboxy containing (phenyl-/heterocyclyl-)methylene substituted azole & azine derivatives and their therapeutic use as antibacterials |
| AU2003286573B2 (en) | 2002-10-23 | 2009-09-10 | Idaho Technology, Inc. | Amplicon melting analysis with saturation dyes |
| ATE458485T1 (de) | 2003-07-11 | 2010-03-15 | Proteologics Inc | Ubiquitin-ligase-hemmer und verwandte verfahren |
| US9657347B2 (en) | 2004-04-20 | 2017-05-23 | University of Utah Research Foundation and BioFire Defense, LLC | Nucleic acid melting analysis with saturation dyes |
| WO2006055970A2 (fr) * | 2004-11-22 | 2006-05-26 | King Pharmaceuticals Research & Development Inc. | Traitement d'amelioration de troubles medies par hif-1 faisant appel a des agonistes du recepteur de l'adenosine a3 |
| CA2705694C (fr) * | 2007-11-21 | 2015-02-24 | Katholieke Universiteit Leuven, K.U.Leuven R & D | Inhibiteurs de l'activite proteolytiques de malt1 et leurs utilisations |
| KR100965726B1 (ko) * | 2007-11-23 | 2010-06-24 | 재단법인서울대학교산학협력재단 | 피리미딘-2,4,6-트라이온 유도체를 함유하는 Ｈｓｐ９０억제제 및 이를 이용한 항암제 |
| EP2271341B1 (fr) * | 2008-05-08 | 2016-08-17 | Nova Southeastern University | Inhibiteurs specifiques des recepteurs du facteur de croissance de l'endothelium vasculaire |
| WO2010018458A2 (fr) * | 2008-08-12 | 2010-02-18 | Crystalgenomics, Inc. | Dérivés de phénol et leurs procédés d'utilisation |
| US8304421B2 (en) * | 2008-09-30 | 2012-11-06 | Vanderbilt University | Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents |
| WO2012065139A2 (fr) * | 2010-11-11 | 2012-05-18 | Board Of Regents, The University Of Texas System | Inhibiteurs de entpd5 |
| JP6209516B2 (ja) * | 2011-08-18 | 2017-10-04 | ニューホープ，エルエルシー | 癌治療に使用するための化合物 |
| AP2014007621A0 (en) | 2011-11-11 | 2014-05-31 | Pfizer | 2-Thiopyrimidinones |
| US9873674B2 (en) * | 2012-09-21 | 2018-01-23 | Cornell University | C-Rel inhibitors and uses thereof |
| CA2895392A1 (fr) | 2012-12-28 | 2014-07-03 | The Board Of Trustees Of The University Of Arkansas | Composes d'indole pour utilisation dans le traitement de l'inflammation et du cancer |
| AU2014254078A1 (en) | 2013-04-19 | 2015-10-15 | Bioventures, Llc | Combretastatin analogs |
| US20160075689A1 (en) * | 2013-04-23 | 2016-03-17 | The Board Of Trustees Of The University Of Arkansas | Polymerase, endonuclease, and helicase inhibitors and methods of using thereof |
| US9974788B2 (en) | 2013-09-26 | 2018-05-22 | Beth Israel Deaconess Medical Center, Inc. | Inhibition of SGK1 in the treatment of heart conditions |
| US9145374B2 (en) * | 2013-11-20 | 2015-09-29 | National Tsing Hua University | Shikimate pathway inhibitors and the use thereof |
| WO2015147204A1 (fr) * | 2014-03-27 | 2015-10-01 | 国立大学法人京都大学 | Composition thérapeutique inhibant le facteur de prolifération de néovascularisation |
| WO2015153635A1 (fr) | 2014-03-31 | 2015-10-08 | Board Of Trustees Of The University Of Arkansas | Analogues triazoles disubstitués |
| WO2015195951A1 (fr) * | 2014-06-18 | 2015-12-23 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Thérapie combinée visant à renforcer l'efficacité anticancéreuse des médicaments à base de platine |
| SG11201705952SA (en) * | 2015-02-04 | 2017-09-28 | Beyondbio Inc | Heterocyclic compound and pharmaceutical composition comprising same |
| WO2016178113A1 (fr) | 2015-05-05 | 2016-11-10 | Pfizer Inc. | 2-thiopyrimidinones |
| KR102260995B1 (ko) * | 2018-11-28 | 2021-06-04 | 국립암센터 | Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3331687A (en) * | 1962-09-24 | 1967-07-18 | Render Belipa G M B H Fa | Electrophotographic material |
| DE2042663A1 (de) * | 1970-08-28 | 1972-03-02 | Agfa-Gevaert Ag, 5090 Leverkusen | Photographisches Trockenkopierverfahren |
| PL77134B1 (fr) * | 1971-12-29 | 1975-02-28 | ||
| US3819595A (en) * | 1972-09-05 | 1974-06-25 | Dow Chemical Co | Nucleation of normally crystalline vinylidene chloride polymers |
| SU1129202A1 (ru) * | 1981-09-08 | 1984-12-15 | Предприятие П/Я Г-4740 | Способ получени 2-арилиденкарбонильных соединений |
| JPS6229570A (ja) * | 1985-07-29 | 1987-02-07 | Kanegafuchi Chem Ind Co Ltd | ３，５−ジイソプロピルベンジリデン複素環式化合物 |
| JPH0196628A (ja) * | 1987-10-08 | 1989-04-14 | Idemitsu Kosan Co Ltd | 有機非線型光学材料 |
| US5141943A (en) * | 1990-04-12 | 1992-08-25 | Brown University Research Foundation | 5-benzyl barbiturate derivatives |
| AU6087894A (en) * | 1993-01-14 | 1994-08-15 | Cell Therapeutics, Inc. | Acetal or ketal substituted therapeutic compounds |
| JPH1048824A (ja) * | 1996-07-31 | 1998-02-20 | Toyobo Co Ltd | 光重合性組成物、それを用いた感光性原版およびその露光方法 |
| BR9913406A (pt) * | 1998-09-04 | 2002-01-29 | Viropharma Inc | Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção |
| ES2299427T3 (es) * | 1999-06-04 | 2008-06-01 | Dana-Farber Cancer Institute, Inc. | Identificacion de compuestos que modifiquen respuestas transcripcionales a la hipoxia. |
-
2000
- 2000-06-05 GB GBGB0013655.6A patent/GB0013655D0/en not_active Ceased
-
2001
- 2001-06-05 AU AU2001260504A patent/AU2001260504A1/en not_active Abandoned
- 2001-06-05 IL IL15301401A patent/IL153014A0/xx unknown
- 2001-06-05 NZ NZ522779A patent/NZ522779A/en unknown
- 2001-06-05 CN CN01810729A patent/CN1433312A/zh active Pending
- 2001-06-05 DE DE60138709T patent/DE60138709D1/de not_active Expired - Fee Related
- 2001-06-05 US US10/297,203 patent/US20030229108A1/en not_active Abandoned
- 2001-06-05 WO PCT/GB2001/002468 patent/WO2001093841A2/fr active IP Right Grant
- 2001-06-05 CA CA002410311A patent/CA2410311C/fr not_active Expired - Fee Related
- 2001-06-05 AT AT01934202T patent/ATE431149T1/de not_active IP Right Cessation
- 2001-06-05 EP EP01934202A patent/EP1305026B1/fr not_active Expired - Lifetime
- 2001-06-05 JP JP2002501414A patent/JP2003535123A/ja active Pending
- 2001-06-05 BR BR0111438-7A patent/BR0111438A/pt not_active Application Discontinuation
-
2002
- 2002-11-20 ZA ZA200209439A patent/ZA200209439B/en unknown
-
2008
- 2008-01-16 US US12/015,208 patent/US20080113993A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR0111438A (pt) | 2003-06-17 |
| EP1305026A2 (fr) | 2003-05-02 |
| CA2410311A1 (fr) | 2001-12-13 |
| AU2001260504A1 (en) | 2001-12-17 |
| IL153014A0 (en) | 2003-06-24 |
| US20030229108A1 (en) | 2003-12-11 |
| ATE431149T1 (de) | 2009-05-15 |
| WO2001093841A2 (fr) | 2001-12-13 |
| NZ522779A (en) | 2004-08-27 |
| US20080113993A1 (en) | 2008-05-15 |
| DE60138709D1 (de) | 2009-06-25 |
| EP1305026B1 (fr) | 2009-05-13 |
| JP2003535123A (ja) | 2003-11-25 |
| CN1433312A (zh) | 2003-07-30 |
| GB0013655D0 (en) | 2000-07-26 |
| CA2410311C (fr) | 2009-12-29 |
| WO2001093841A3 (fr) | 2002-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200209439B (en) | Barbituric acid analogs as therapeutic agents. | |
| Sharma et al. | Role of LDH in tumor glycolysis: regulation of LDHA by small molecules for cancer therapeutics | |
| Howes et al. | The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures | |
| Lai et al. | Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches | |
| ES2219670T3 (es) | Utilizacion de compuestos de pirazola para el tratamiento de la glomerulonefritis, cancer, ateroesclerosis o restenosis. | |
| Peralta-Leal et al. | PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases | |
| Wilkinson et al. | AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis | |
| TWI310684B (en) | Synergistic pharmaceutical kits for treating cancer | |
| KR101667641B1 (ko) | 데시타빈 및 프로카인과 같은 ｄｎａ 메틸전이효소 저해제와 사팍시타빈 또는 ｃｎｄａｃ의 조합 | |
| Perea et al. | CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation | |
| EP1259234B9 (fr) | Composes 3-heteroarylidenyl-2-indolinone destines a moduler l'activite des proteines kinases et a etre utilises en chimiotherapie du cancer | |
| HU229263B1 (en) | The use of pharmaceutical compositions containing 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation | |
| JP6949859B2 (ja) | Ｄｂａｉｔ分子の全身投与によるガンの処置 | |
| AU2006318428A1 (en) | Method of modulating stress-activated protein kinase system | |
| MX2009000713A (es) | Inhibidores de jak para el tratamiento de trastornos mieloproliferativos. | |
| JP2008514726A (ja) | ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法 | |
| CA2947604A1 (fr) | Polytherapies ciblant des mitochondries pour une cancerotherapie | |
| WO2014140072A1 (fr) | Étoposide et leurs promédicaments pour l'utilisation dans le ciblage de cellules souches cancéreuses | |
| JPH06509333A (ja) | ニューロトロフィン活性に対する方法およびアッセイ系 | |
| KR101892908B1 (ko) | 글루코코르티코이드계 화합물을 포함하는 비소세포성 폐암 치료용 약학 조성물 | |
| JP6373252B2 (ja) | オーロラキナーゼ阻害薬を使用する癌の治療方法 | |
| EP1555021A1 (fr) | Combinaisons d'un inhibiteur de la voie du mévalonate et d'un agoniste PPAR-gamma pour le traitement du cancer | |
| Hsu et al. | Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor | |
| Takeuchi et al. | Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression | |
| JP2007513967A (ja) | 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物 |